Presentation

Academic

  • Building a Biomedical Research Culture and Infrastructure: Fundamental Tools.  Keynote Speaker, First Encounter for Scientific Research.  River Plate Adventist University School of Health Sciences, Entre Rios, Argentina.   (11/2012)

Poster

  • Martinez SR, Sanchez-Hernandez ES, Chen XS, Duran A, Wang CH, Casiano CA (2019).  Glucocorticoid receptor interacts with beta-catenin to promote stemness and therapy resistance in prostate cancer cells. 12th AACR Conference on the Science of Cancer Health Disparities.  September 20-23, San Francisco, CA.  (09/2019)
  • Woods-Burnham L, Love A, Cajigas-DuRoss CK, Stiel L, Sanchez ES, Amponsah K, Montgomery S, Wilson C, Casiano CA (2017).   Glucocorticoid-mediated upregulation of stress oncoproteins: implications for prostate cancer health disparities.  Annual AACR Meeting.  April 2-5, Washington DC. (04/2017)
  • Diaz-Osterman CJ, Sanchez T, and Casiano CA (2019).  Differential reactivity and cell migration inhibitory functions of autoantibodies to Enolase 1 from African American and European American men with prostate cancer. 12th AACR Conference on the Science of Cancer Health Disparities.  September 20-23, San Francisco, CA (09/2020)
  • Ortiz-Hernandez GL, Sanchez-Hernandez ES, Casiano CA (2020).  Interaction of LEDGF/p75 with oncogenic transcription factors in docetaxel resistant prostate cancer cells.   AACR Annual Meeting (Virtual) (06/2020)
  • Ortiz-Hernandez GL, Sanchez-Hernandez ES, Martinez SR, Mahler M, Casiano CA (2019). Anti-DFS autoantibodies as probes to characterize the DFS70/LEDGFp75 interactome.  14th Dresden Symposium on Autoantibodies.  September 10-13, Dresden, Germany. (09/2019)
  • Sanchez TW, Martinez SR, Ortiz-Hernandez GL, Sanchez-Hernandez E, Montgomery C, Becerra B, Dorsey T, Wang-Johanning F, Ambs S, Casiano CA (2019).  Autoantibodies to human endogenousretrovirus K envelope protein (HERV-K ENV) are associated with features of prostate cancer aggressiveness in African American men.  Annual AACR Meeting.  March 30-April 3, Atlanta, GA. (04/2019)
  • Ortiz-Hernandez GL, Martinez SR, Sanchez-Hernandez E, Rios-Colon L, Cajigas-DuRoss CK, Sanchez TW, Neamati T, Casiano CA (2019).  The cMYC-associated transcription factor JPO2 is upregulated in taxane resistant prostate cancer cells and interacts with the stress oncoprotein LEDGF/p75.   Annual AACR Meeting.  March 30-April 3, Atlanta, GA. (04/2019)
  • Martinez SR, Diaz-Osterman CJ, Chen XS, Wang C, Zhang L, Casiano CA (2019). Role of the glucocorticoid receptor/beta-catenin interaction in prostate cancer stem cell survival and chemoresistance. Annual AACR Meeting.  March 30-April 3, Atlanta, GA. (04/2019)
  • Woods-Burnham L, Cajigas-DuRoss CK, Basu A, Sanchez ES, Love A, Casiano CA (2018). Glucocorticois trigger GR-mediated expression of the chemoresistance-associated proteins LEDGF/p75 and Clusterin: implications for health disparities.  Annual AACR Meeting.  April 14-18, Chicago, IL. (04/2018)
  • Cajigas-DuRoss CK, Woods-Burnham L, Ramirez J, Chen X, Wang C, Casiano CA (2018).  RNA sequencing analysis of taxane-resistant prostate cancer cells reveals potential candidate genes for therapeutic targeting.   Annual AACR Meeting.  April 14-18, Chicago, IL. (04/2018)
  • Sanchez TW, Zhang G, Li J, Dai L, Mirshahidi S, Wall NR, Yates C, Wilson C, Montgomery S, Zhang JY, Casiano CA (2017).  Targeting the tumor associated autoantigen alpha enolase in prostate cancer.  Annual AACR Meeting.  April 2-5, Washington DC. (04/2017)
  • Cajigas-DuRoss CK, Rios-Colon L, Woods-Burnham L, Casiano CA (2017). Co-targeting the stress survival proteins LEDGF/p75 and Clusterin to resensitize chemoresistant prostate cancer cells to docetaxel.   Annual AACR Meeting.  April 2-5, Washington DC. (04/2017)

Other

  • Community talk on “Cancer de la prostata; que debemos saber? (Prostate cancer: what we need to know)” – sponsored by Andrews University extension certificate course on health sciences and nutrition for Hispanics, La Sierra, CA. (08/2019)
  • Panelist, United Service to Africa Webinar Series. “COVID-19 vaccines: the good and the ugly” (09/2020)
  • Panelist, “Health disparities in the era of COVID-19 and beyond”, a Health Watch Presentation for the community sponsored by the Ghanian SDA Church in Riverside CA. (07/2020)
  • Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: many lessons learned but still many questions.  Exagen, Vista CA     (12/2019)
  • Panelist, LLU EXSEED Program for K-12 educators: “Reflections of Diversity and Equity in the STEM Professions” (06/2020)
  • Presenter on the topic of “Prostate Cancer Health Disparities Research at Loma Linda University”, LLU Cancer Center Celebration of Life event (06/2019)
  • Community talk on “Prostate cancer: what we need to know”. Abundant Living Family Church, Hesperia CA. (06/2018)
  • Autoantibodies to DFS70/LEDGF/p75: Novel Biomarkers for the Exclusion of Systemic Autoimmune Rheumatic Diseases. Inova Diagnostics U.S. Strategic Meeting, La Jolla CA.   (12/2016)
  • Community talk on “Prostate cancer: medical aspects and research at LLU”. Flatbush SDA Church, Brooklyn NY. (05/2015)
  • Community talk on “Prostate cancer incidence and mortality in men of African ancestry”.  Ghanaian SDA Church, Riverside CA (11/2014)
  • Antinuclear autoantibodies: diagnostic tools, molecular probes, and guides for immunotherapy.  Guest Speaker, Inova Research and Innovation Summit, San Diego CA (04/2019)

Research

  • The enigmatic DFS70/LEDGFp75 autoantibody-autoantigen system: from basic biology to clinical applications. 12th Dresden Symposium on Autoantibodies.   Dresden, Germany.  (09/2015)
  • LEDGF/p75: a stress survival protein at the crossroads between AIDS, cancer, and autoimmunity.   University of Sao Paulo, Brazil.   (08/2020)
  • Current challenges in understanding the significance of the DFS70 autoantibody-autoantigen system.  14th Dresden Symposium on Autoantibodies.   Dresden, Germany. (09/2019)
  • Twenty years of research on the DFS70/LEDGF autoantigen: still many unanswered questions.  11th International Congress of Autoimmunity, Lisbon, Portugal.   (05/2018)
  • Autoantibodies to the nuclear autoantigen DFS70/LEDGFp75: what are they trying to tell us? Marques de Valdecilla Hospital, University of Cantabria, Santander, Spain.  (09/2017)
  • Alpha-enolase, a common autoantigen in infection, autoimmunity, and cancer. 13th Dresden Symposium on Autoantibodies.   Dresden, Germany.  (09/2017)
  • The DFS70/LEDGFp75 antigen: clues towards a better understanding of anti-DFS autoantibodies.  10th International Congress of Autoimmunity.  Leipzig, Germany.   (04/2016)
  • Recent advances on the immunobiology of the DFS70/LEDGF autoantigen.  International Course of Autoimmunity, Mexico City (09/2014)
  • Diagnostic utility of tumor associated autoantigen panels for autoantibody profiling in cancer: recent advances and future directions. 12th Dresden Symposium on Autoantibodies.   Dresden, Germany.  (09/2015)
  • Immunoproteomics profiling of prostate cancer-associated autoantibodies in diverse populations.  Global Conference on Prostate Cancer health Disparities.  Montego Bay, Jamaica.  (10/2014)
  • Role of intracellular autoantigens in the development of autoimmunity. International Course of Autoimmunity, Mexico City (09/2014)
  • Cancer-associated autoantibodies: lessons from prostate cancer.  12th International Workshop on Autoantibodies and Autoimmunity.  Sao Paulo, Brazil.   (08/2014)
  • The DFS70/LEDGFp75 autoantigen at the interface between AIDS, cancer, and autoimmunity.  12th International Workshop on Autoantibodies and Autoimmunity.  Sao Paulo, Brazil.   (08/2014)
  • Inflammation, Oxidative Stress, and Cancer.  Keynote Speaker, First Encounter for Scientific Research.  River Plate Adventist University School of Health Sciences, Entre Rios, Argentina.   (11/2012)
  • Autoantibodies against LEDGF/DFS70: natural autoantibodies or sensors of an augmented state of cellular oxidative stress? 9thDresden Symposium on Autoantibodies.   Dresden, Germany.  (09/2009)
  • The emerging role of LEDGF in malignant transformation and chemoresistance. Division of Molecular Medicine, Catholic University of Leuven, Belgium.   (12/2008)
  •  “Team Science”, LLU School of Medicine Basic Science Retreat (10/2015)
  • "Prostate Cancer Research in the Casiano Lab:  Focus on Chemoresistance and Health Disparities”, LLUH Research Oversight Committee (04/2020)
  • “Prostate Cancer Research in the Casiano Lab:  Targeting Therapy Resistance and Health Disparities” LLUH Board of Trustees (08/2020)